Company Description
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel.
It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions.
The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016.
Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
| Country | United States |
| Founded | 1999 |
| IPO Date | Jan 25, 2007 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Amy Trombly |
Contact Details
Address: 5445 Conestoga Court, Suite 150 Boulder, Colorado 80301 United States | |
| Phone | 800 759 9305 |
| Website | sonomapharma.com |
Stock Details
| Ticker Symbol | SNOA |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001367083 |
| CUSIP Number | 83558L204 |
| ISIN Number | US83558L2043 |
| Employer ID | 68-0423298 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Amy M. Trombly | Chief Executive Officer, President and Director |
| Jerome J. Dvonch | Chief Financial Officer |
| Bruce Thornton | Executive Vice President, Chief Operating Officer and Corporate Secretary |
| John Dal Poggetto | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 21, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Oct 22, 2024 | 8-K | Current Report |
| Sep 20, 2024 | 8-K | Current Report |
| Sep 20, 2024 | 424B5 | Filing |
| Aug 28, 2024 | 8-K | Current Report |
| Aug 23, 2024 | 8-K | Current Report |
| Aug 23, 2024 | 424B5 | Filing |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |